Two Partnerships Tackle Status Quo In Hemophilia, One With Long-Acting Coagulation Factors, Other With Increased Access To Therapy
Executive Summary
Although not among the more prominent diseases in the biopharmaceutical business, hemophilia offers significant market opportunity just the same, especially considering that people with the disease, a genetic blood disorder caused by scarcity or absence of coagulation factors, are underserved